Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Genetically Engineered Cells (19(T2)28z1XX TRAC-CAR T-Cells) for the Treatment of CD19-Positive Relapsed or Refractory B-Cell Lymphoma

Trial Status: closed to accrual

This phase I trial studies the safety, side effects, and best dose of genetically engineered cells called 19(T2)28z1XX TRAC-chimeric antigen receptor (CAR) T-cells in treating patients with CD19-positive B-cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). 19(T2)28z1XX TRAC-CAR T cells are made in the laboratory using collected white blood cells (T-cells). T cells are important protective cells of the immune system. The T cells have been genetically modified (changes are made to the DNA or genes) to help them identify, fight, or kill cancer cells. A virus (retrovirus) and a new technology called CRISPR/Cas9 are used to introduce a gene to a specific location (called TRAC) that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells to identify and kill cancer cells. The retrovirus then becomes inactive. The 19(T2)28z1XX TRAC-CAR T cells can recognize a protein called CD19, which is found on the surface of B-cell cancer cells, and destroy those cells.